Magnesium Oxide–Amphetamine (Dexamfetamine) Co-Coadministration Effects
No patient-level pharmacokinetic or pharmacodynamic interaction studies specifically evaluating magnesium oxide coadministration with dexamfetamine (amfexa) were identified in the reviewed sources.
Pharmacokinetic Mechanisms Affected by Magnesium Oxide
Magnesium oxide is a mineral antacid that can raise gastric pH, which can change the solubility and absorption rate of drugs whose absorption is pH dependent. [1]
Magnesium-containing antacids can also alter urine pH, which can affect renal elimination of weak base drugs such as amphetamine. [1]
Amphetamine elimination shows strong dependence on urinary pH, with longer half-life under basic urinary pH conditions and shorter half-life under acidic urinary pH conditions. [2]
Duration of Action Effects
If magnesium oxide increases urinary pH, amphetamine exposure is expected to persist longer due to reduced renal clearance of weak bases under basic urine conditions. [2]
A longer systemic exposure is expected to translate into increased duration of clinically observable stimulant effects (attention, wakefulness, appetite suppression), based on the pH–half-life relationship for amphetamine. [2]
Clinical Effects (Magnitude and Direction)
Antacid effects on drug exposure can include increased absorption rate for some orally administered drugs due to increased gastric pH. [3]
Because antacid effects depend on the substrate drug’s pH-dependent absorption and local formulation factors, the direction of change in dexamfetamine onset (faster vs unchanged) is best treated as uncertain for dexamfetamine specifically in the absence of direct PK studies. [4]
For duration, urinary pH–mediated changes provide a more consistent pharmacologic pathway for amphetamine-class drugs. [2]
Timing and Practical Management Used in pH-Interaction Avoidance
A dose-separation strategy is commonly recommended to mitigate short-duration gastric pH elevation from antacids by separating administration times of the antacid and the oral substrate medication. [1]
Safety and Monitoring Considerations
Increased stimulant effect duration raises the likelihood of adverse effects typical for amphetamine-class agents, including insomnia, reduced appetite, and increased sympathetic symptoms, which correlate with higher or prolonged exposure. [2]
Monitoring for change in timing of onset and total “wearing off” window is recommended when magnesium oxide is initiated, discontinued, or when dosing schedules change, due to potential shifts in pH-dependent absorption and elimination. [1]